GlassScriptPhysician profile
Tracy Klayton
NPI 1497948947
$3,061.83
in general payments reported to CMS, 2019-2025
36 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 87% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2022: $36.39 · 2023: $231 · 2024: $1,160 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.66 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $426.03 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| Novartis Pharmaceuticals Corporation | $262.56 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $230.10 | 2024-2025 | Libtayo |
| Incyte Corporation | $222.87 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Elekta, INC. | $216.38 | 2024 | |
| Lilly USA, LLC | $213.01 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Sirtex Medical INC | $127.55 | 2019 | |
| Glaxosmithkline, LLC. | $116.19 | 2023-2025 | Ojjaara, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $104.33 | 2024-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Merck Sharp & Dohme LLC | $95.58 | 2024-2025 | Keytruda, Keytruda Qlex |
| Pharmaessentia USA Corporation | $93.54 | 2024-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $90.30 | 2024-2025 | |
| Eisai INC. | $79.33 | 2024-2025 | |
| Novocure INC. | $74.65 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Astrazeneca Pharmaceuticals LP | $71.61 | 2022-2025 | Imfinzi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $69.49 | 2025 | Beleodaq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Tactile Systems Technology INC | $53.88 | 2019-2025 | Flexitouch Plus, Nimbl |
| Genentech USA, INC. | $51.92 | 2023-2024 | Venclexta, Phesgo |
| Exelixis INC. | $50.41 | 2025 | Cabometyx |
| Janssen Biotech, INC. | $33.78 | 2024-2025 | Rybrevant, Darzalex, Tecvayli |
| Abbvie INC. | $31.87 | 2024 | |
| Azurity Pharmaceuticals, INC. | $30.80 | 2025 | Danziten |
| E.R. Squibb & Sons, L.L.C. | $27.80 | 2023 | |
| Rigel Pharmaceuticals, INC. | $26.78 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $24.63 | 2023 | Tazverik |
| Geron Corporation | $20.29 | 2025 | Rytelo |
| Pfizer INC. | $19.09 | 2025 | |
| Tersera Therapeutics LLC | $18.42 | 2024 | Xermelo |
| Genzyme Corporation | $17.82 | 2023 | |
| Sobi, INC | $17.60 | 2024 | |
| Taiho Oncology, INC. | $17.52 | 2024 | |
| Stemline Therapeutics INC. | $17.51 | 2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $16.86 | 2025 | Ultomiris |
| Sumitomo Pharma America, INC. | $16.10 | 2023 | Orgovyx |
| Adc Therapeutics America, INC. | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Klayton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.